Skip to main content

glasdegib (Daurismo®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal TA646: Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)

Medicine details

Medicine name glasdegib (Daurismo®)
Formulation 25 mg and 100 mg film-coated tablets
Reference number 3661
Indication

In combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy

Company Pfizer Ltd
BNF chapter Malignant disease & immunosuppression
Submission type N/A
Status Excluded due to NICE appraisal
Date of issue 02/09/2020
NICE guidance

TA646: Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)